Parkside Financial Bank & Trust Raises Stock Position in Sanofi (NASDAQ:SNY)

Parkside Financial Bank & Trust grew its holdings in Sanofi (NASDAQ:SNY) by 435.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189 shares of the company’s stock after purchasing an additional 1,780 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Sanofi were worth $109,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SNY. Jennison Associates LLC purchased a new position in shares of Sanofi in the 4th quarter valued at $7,932,000. OLD National Bancorp IN raised its stake in shares of Sanofi by 5.9% in the 4th quarter. OLD National Bancorp IN now owns 28,379 shares of the company’s stock valued at $1,411,000 after acquiring an additional 1,572 shares during the period. Cetera Trust Company N.A purchased a new position in shares of Sanofi in the 4th quarter valued at $300,000. Grandfield & Dodd LLC raised its stake in shares of Sanofi by 1.5% in the 4th quarter. Grandfield & Dodd LLC now owns 381,978 shares of the company’s stock valued at $18,996,000 after acquiring an additional 5,600 shares during the period. Finally, abrdn plc purchased a new position in shares of Sanofi in the 4th quarter valued at $7,889,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SNY. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley assumed coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average price target of $55.00.

Sanofi Stock Performance

Sanofi stock opened at $49.36 on Friday. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82. The company has a market capitalization of $124.86 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 1.41 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The firm’s fifty day moving average price is $47.65 and its 200 day moving average price is $48.45.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, research analysts forecast that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is presently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.